D-1837-2019 Class I Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-1837-2019 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Jul 9, 2019 and is designated Class I. Reason for recall: Failed dissolution specifications : failed results at the 3-month stability time point. The recall status is terminated (terminated May 7, 2021). Affected quantity: 11,412 cartons/34,236 blister cards/28 tablets each card.

Recall details

Product Type
Drugs
Report Date
Aug 7, 2019
Initiation Date
Jul 9, 2019
Termination Date
May 7, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,412 cartons/34,236 blister cards/28 tablets each card

Product description

Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/0.02 mg, packaged into a carton containing 3 blister cards each blister card contains 28-film coated, biconvex tablets, Rx Only, Manufactured by: Cyndea Pharma, S.L., Olvega (Soria), 42110 Spain, Distributed by: Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, 21801 USA, NDC 59746-763-43

Reason for recall

Failed dissolution specifications : failed results at the 3-month stability time point.

Distribution pattern

USA Nationwide

Code information

Lot #: 183222, Exp 11/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1837-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1837-2019. Report a data issue: hello@regdatalab.com.